Eastern Bank Sells 907 Shares of Agilent Technologies, Inc. $A

Eastern Bank lessened its holdings in Agilent Technologies, Inc. (NYSE:A) by 1.5% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 59,045 shares of the medical research company’s stock after selling 907 shares during the period. Eastern Bank’s holdings in Agilent Technologies were worth $6,968,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of the business. Vanguard Group Inc. increased its position in Agilent Technologies by 0.7% in the first quarter. Vanguard Group Inc. now owns 33,408,626 shares of the medical research company’s stock worth $3,908,141,000 after purchasing an additional 240,965 shares during the last quarter. Pictet Asset Management Holding SA increased its position in Agilent Technologies by 2.5% in the first quarter. Pictet Asset Management Holding SA now owns 5,341,870 shares of the medical research company’s stock worth $624,888,000 after purchasing an additional 128,131 shares during the last quarter. Generation Investment Management LLP increased its position in Agilent Technologies by 19.8% in the first quarter. Generation Investment Management LLP now owns 4,983,556 shares of the medical research company’s stock worth $582,976,000 after purchasing an additional 824,243 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in Agilent Technologies by 18.7% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 3,836,105 shares of the medical research company’s stock worth $448,748,000 after purchasing an additional 604,124 shares during the last quarter. Finally, Impax Asset Management Group plc increased its position in Agilent Technologies by 3.6% in the first quarter. Impax Asset Management Group plc now owns 2,931,794 shares of the medical research company’s stock worth $342,961,000 after purchasing an additional 102,365 shares during the last quarter.

Agilent Technologies Stock Down 2.5%

Shares of A opened at $136.62 on Friday. The firm has a market capitalization of $38.73 billion, a P/E ratio of 32.07, a P/E/G ratio of 4.57 and a beta of 1.26. Agilent Technologies, Inc. has a 12-month low of $96.43 and a 12-month high of $153.84. The company has a current ratio of 2.25, a quick ratio of 1.71 and a debt-to-equity ratio of 0.53. The firm has a fifty day moving average price of $125.04 and a 200-day moving average price of $117.05.

Agilent Technologies (NYSE:A) last issued its earnings results on Wednesday, August 27th. The medical research company reported $1.37 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $1.37. The firm had revenue of $1.74 billion during the quarter, compared to analyst estimates of $1.67 billion. Agilent Technologies had a net margin of 17.97% and a return on equity of 25.51%. The business’s revenue was up 10.1% on a year-over-year basis. During the same period in the previous year, the firm earned $1.32 earnings per share. Agilent Technologies has set its FY 2025 guidance at 5.560-5.590 EPS. Q4 2025 guidance at 1.570-1.600 EPS. Equities research analysts expect that Agilent Technologies, Inc. will post 5.58 earnings per share for the current year.

Agilent Technologies Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 22nd. Investors of record on Tuesday, September 30th will be issued a $0.248 dividend. This represents a $0.99 annualized dividend and a dividend yield of 0.7%. The ex-dividend date is Tuesday, September 30th. Agilent Technologies’s payout ratio is presently 23.24%.

Wall Street Analysts Forecast Growth

A has been the subject of several recent analyst reports. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Agilent Technologies in a research note on Wednesday. Barclays lifted their price objective on shares of Agilent Technologies from $125.00 to $150.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 2nd. JPMorgan Chase & Co. lifted their price objective on shares of Agilent Technologies from $155.00 to $165.00 and gave the stock an “overweight” rating in a research note on Thursday. UBS Group raised shares of Agilent Technologies from a “neutral” rating to a “buy” rating and lifted their price objective for the stock from $130.00 to $170.00 in a research note on Wednesday. Finally, Wells Fargo & Company lifted their price objective on shares of Agilent Technologies from $140.00 to $150.00 and gave the stock an “overweight” rating in a research note on Monday, September 15th. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $148.69.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.